Philogen develops innovative targeted pharmaceuticals, which are highly specific to markers found in tumors and in other serious conditions but are undetectable in normal tissues.
An integrated platform spans discovery, preclinical testing, in-house GMP manufacturing, and clinical development.
Why Ligand-based targeting
Non-targeted therapy
Distribution throughout the body
Insufficient accumulation at the tumor site
Ligand-based targeted therapy
Activity at the site of disease
Spare healthy tissues
Conventional drugs do not localize at the site of disease. A selective delivery of therapeutics that bind to disease-associated targets can offer a benefit to patients.
Connected platform
A fully integrated platform
01 · Target discovery
Find accessible disease targets
Chemical proteomics identifies disease-associated proteins that can be reached by an antibody or small-molecule ligand.
Method detail+
Working with Philochem and ETH Zürich, Philogen scientists developed proteomics methods for the characterization of accessible markers of pathology. In a simple setup, cell lines can be submitted to surface biotinylation followed by capture on streptavidin resin and mass spectrometric analysis of tryptic peptides. In a more complex setup, in vivo biotinylation procedures of rodent models of pathology enable the chemical proteomic characterization of vascular proteins in health and in disease. The work has also extended to ex-vivo perfusion of surgically resected human organs with cancer.
02 · Ligand discovery
Select the ligand
DNA-encoded chemical libraries, antibody phage display and peptide phage display are screened to retain binders to a chosen target.
Philochem has been pioneer in the field of DNA-Encoded Chemical Libraries, a revolutionary technology that allows the synthesis and screening of molecular repertoires with billions of chemical compounds.
03 · Targeted products
Generation of innovative targeted products
A selected antibody, peptide, or small molecule ligand specific to a disease-associated target is engineered to carry a potent payload (e.g., cytotoxic drugs, cytokines, or radionuclides).
Antibodies carry cytokines.Peptide and small molecule ligands carry drugs, radionuclide, or other payloads.
04 · Manufacture and develop
Continue into GMP and the clinic
Philogen manufactures its own products under GMP and advances a proprietary clinical and preclinical pipeline.
The same capabilities also support selected industrial and academic collaborations.
